Clinical trials: Stage III Breast Cancer
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Phase III Study of 5tx vs 15tx of RT (X-rays or Protons) Including RNI in Breast Cancer Patients
This phase III trial compares the rate of complications of x-ray therapy versus proton beam radiation therapy after breast conserving surgery or mastectomy in treating patients with breast cancer.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- NCT04443413
- Testing
- Proton Beam Radiation Therapy, Questionnaire Administration, X-ray Therapy
- Where
- 3 sites in United States
- Volunteers
- 146 people
- Sponsor
- Mayo Clinic
Breast Cancer
Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00003680
- Testing
- CMF regimen, cyclophosphamide, fluorouracil
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- Scottish Cancer Therapy Network
Breast Cancer
Timing of Menstrual Cycle and Surgery in Treating Premenopausal Women With Stage I, Stage II, or Stage III Breast Cancer
RATIONALE: The timing of breast cancer surgery within the menstrual cycle may affect outcome. It is not yet known if treatment is more effective during the initial or final phase of the menstrual cycle.
- Trial name
- NCT00005079
- Testing
- conventional surgery
- Where
- 2 sites in United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Carcinoma Breast Stage I, HER2 Positive Breast Cancer
Pre Operative Trastuzumab in Operable Breast Cancer
Background Information and Rationale: Trastuzumab is a humanized monoclonal antibody that acts extracellularly on the erbB-2 receptor.Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the human epidermal…
- Trial name
- NCT01785420
- Testing
- Trastuzumab
- Where
- India
- Volunteers
- 1,100 people
- Sponsor
- Dr Rajendra A. Badwe
Breast Cancer
Herceptin Followed by Chemotherapy in Treating Women With Metastatic Breast Cancer That Overexpresses HER2
RATIONALE: To compare efficacy, toxicity and quality of life of the sequential administration of Her alone followed, at PD, by the combination with Chemotherapy (Arm A) vs.
- Trial name
- NCT00004935
- Testing
- Herceptin™ (Her), Herceptin™ (Her) + chemo
- Where
- 17 sites in Italy, Switzerland
- Volunteers
- 175 people
- Sponsor
- Swiss Cancer Institute
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
High-Dose Chemotherapy and Autologous Blood Cell Transplantation in Treating Patients With Primary, Locally Advanced, or Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00003068
- Testing
- amifostine trihydrate, cyclophosphamide, mitoxantrone hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Arizona
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments
Comparison of olaparib vs. physician's choice of single agent standard of care non-platinum based chemotherapy in patients with germline Breast Cancer susceptibility gene (gBRCA) mutated ovarian cancer who have progressed at…
- Trial name
- SOLO3 (NCT02282020)
- Testing
- OLAPARIB, Single agent chemotherapy
- Where
- 94 sites in United States, Argentina and 11 more
- Volunteers
- 266 people
- Sponsor
- AstraZeneca
Advanced Malignant Neoplasm, Advanced Melanoma
Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study
This trial studies the genetic analysis of blood and tissue samples from patients with cancer that has spread to other anatomic sites (advanced) or is no longer responding to treatment.
- Conditions
- Advanced Malignant Neoplasm, Advanced Melanoma, Advanced Renal Cell Carcinoma, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- NCT03707574
- Testing
- Biospecimen Collection
- Where
- 144 sites in United States, Puerto Rico
- Volunteers
- 64 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
PET in Breast Cancer Receiving Neoadjuvant Chemotherapy
Prognostic factors in locally advanced breast cancer treated with neoadjuvant chemotherapy differ from those of early breast cancer.
- Trial name
- DA-PET (NCT01396655)
- Testing
- docetaxel (75 mg/m2) and doxorubicin (50 mg/m2)
- Volunteers
- 78 people
- Sponsor
- Seoul National University Hospital
Breast Cancer
A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
This Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial in China will evaluate the efficacy and safety of pertuzumab + trastuzumab + docetaxel compared with placebo + trastuzumab + docetaxel in…
- Trial name
- PUFFIN (NCT02896855)
- Testing
- Docetaxel, Pertuzumab, Trastuzumab
- Where
- 15 sites in China
- Volunteers
- 243 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Prolonged Tamoxifen Compared With Shorter Tamoxifen in Treating Patients Who Have Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by reducing the production of estrogen.
- Trial name
- NCT00003016
- Testing
- tamoxifen citrate, adjuvant therapy
- Where
- United Kingdom
- Volunteers
- 20,000 people
- Sponsor
- University of Oxford
Breast Cancer
Maintenance Treatment With Capecitabine Versus Observation in Breast Cancer Patients
This is a prospective, open-label, randomized phase III study assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer.
- Trial name
- NCT00130533
- Testing
- Capecitabine
- Where
- 48 sites in Spain
- Volunteers
- 876 people
- Sponsor
- Spanish Breast Cancer Research Group
Breast Cancer
Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2
Randomized phase II trial to study the effectiveness of chemotherapy with paclitaxel and the monoclonal antibody trastuzumab followed by chemotherapy in treating women who have stage II or stage IIIA breast cancer that…
- Trial name
- NCT00003992
- Testing
- trastuzumab, cyclophosphamide, doxorubicin hydrochloride
- Where
- 45 sites in United States, South Africa
- Volunteers
- 200 people
- Sponsor
- National Cancer Institute (NCI)
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer
Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer
This phase II trial studies the impact of a presurgical endocrine therapy, consisting of goserelin with letrozole or anastrozole on the treatment of premenopausal patients with stage II-III estrogen receptor-positive (ER+) and…
- Conditions
- Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
- Trial name
- NCT01368263
- Testing
- goserelin acetate, letrozole, anastrozole
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Washington University School of Medicine
Breast Cancer
Chemosensitivity During Phases of the Menstrual Cycle in Breast Cancer Patients
This study is a prospective, multicenter study in which a serum sample will be collected at the day of starting neo adjuvant treatment in breast cancer patients
- Trial name
- Chemosense (NCT06273800)
- Testing
- Blood sample
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer Female
High-dose Chemotherapy With Hematopoietic Stem-cell Rescue for High-risk Breast Cancer: Long-term Follow-up
Collection of follow-up data from the original trial patient cohort.
- Trial name
- NCT03087409
- Where
- 10 sites in Netherlands
- Volunteers
- 885 people
- Sponsor
- University Medical Center Groningen
Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
This Phase III, randomized, double-blind, placebo-controlled, multicenter study will evaluate the efficacy and safety of giredestrant combined with palbociclib compared with letrozole combined with palbociclib in patients with…
- Trial name
- NCT04546009
- Testing
- Giredestrant, Letrozole, Palbociclib
- Where
- 255 sites in United States, Argentina and 28 more
- Volunteers
- 992 people
- Sponsor
- Hoffmann-La Roche
Hand Foot Syndrome
Treatment of Hand and Foot Syndrome With Traditional Chinese Medicine Formula LC09 in Patients Who Are Receiving Capecitabine for Colorectal and/or Breast Cancer
RATIONALE: Hand foot syndrome may be treated or reduced by soaking Traditional Chinese Medicine Formula LC09 in patients receiving capecitabine for colorectal and/or breast cancer.
- Trial name
- NCT02794493
- Testing
- Traditional Chinese Medicine Formula LC09
- Volunteers
- 156 people
- Sponsor
- China-Japan Friendship Hospital
Breast Cancer
Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer
This neoadjuvant trial for patients with TNBC and/or gBRCA breast cancer, aims to investigate the safety and efficacy (improvement in pathological Complete Response at surgery) of concurrent platinum-based chemotherapy with…
- Trial name
- PARTNER (NCT03150576)
- Testing
- Olaparib, Paclitaxel and Carboplatin
- Where
- 30 sites in United Kingdom
- Volunteers
- 780 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Breast Cancer
Biomarkers in Native American Women With Breast Cancer
RATIONALE: Studying samples of tumor tissue in the laboratory from Native American women with breast cancer may help doctors identify and learn more about biomarkers related to breast cancer in these patients.
- Trial name
- NCT00898976
- Testing
- immunohistochemistry staining method, laboratory biomarker analysis
- Volunteers
- 120 people
- Sponsor
- Alliance for Clinical Trials in Oncology